Delfi Diagnostics, Inc. filed a Form D with the Securities and Exchange Commission on 2025-12-18.
Delfi Diagnostics, Inc. filed a Form D notice of an exempt securities offering with the SEC on December 18, 2025. The filing reports $34.33M sold. Its industry group is Biotechnology. It names Susan Tousi (Executive Officer, Director), Peter Bach (Executive Officer), Amoolya Singh (Executive Officer) (SEC Form D, December 18, 2025).
Sell to companies like Delfi Diagnostics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2025-12-18 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Delfi Diagnostics, Inc.
Free to see. No signup.
More on the people and the money behind Delfi Diagnostics, Inc., from the filings we hold.
Biotechnology raises by companies based in California, filed in December 2025, largest first.
Get an email when Delfi Diagnostics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Delfi Diagnostics, Inc. raises, hires or launches. No email unless you switch it on.
Watch Delfi Diagnostics, Inc. →Get the full cited report on Delfi Diagnostics, Inc.
What the filing shows about Delfi Diagnostics, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Delfi Diagnostics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
Saved here on this device in the meantime, so nothing is lost either way.
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Order the Full Report on Delfi Diagnostics, Inc. See pricing
Trailing twelve months. 759 filings in Biotechnology, totalled by week. The dot is this raise, $34.33M, on the same scale — one filing against the whole group's total, so it sits low by construction.
Susan Tousi is named as Executive Officer and Director on the Form D that Delfi Diagnostics, Inc. filed with the SEC on 18 December 2025, one of 11 people that filing names.
Peter Bach is named as Executive Officer on the Form D that Delfi Diagnostics, Inc. filed with the SEC on 18 December 2025, one of 11 people that filing names.
Amoolya Singh is named as Executive Officer on the Form D that Delfi Diagnostics, Inc. filed with the SEC on 18 December 2025, one of 11 people that filing names.
Lee-Ann Smith-Freeman is named as Executive Officer on the Form D that Delfi Diagnostics, Inc. filed with the SEC on 18 December 2025, one of 11 people that filing names.
Victor Velculescu is named as Director on the Form D that Delfi Diagnostics, Inc. filed with the SEC on 18 December 2025, one of 11 people that filing names.
Greg Yap is named as Director on the Form D that Delfi Diagnostics, Inc. filed with the SEC on 18 December 2025, one of 11 people that filing names.
Rishi Gupta is named as Director on the Form D that Delfi Diagnostics, Inc. filed with the SEC on 18 December 2025, one of 11 people that filing names.
Michael Dybbs is named as Director on the Form D that Delfi Diagnostics, Inc. filed with the SEC on 18 December 2025, one of 11 people that filing names.
Elizabeth Homans is named as Director on the Form D that Delfi Diagnostics, Inc. filed with the SEC on 18 December 2025, one of 11 people that filing names.
Justin Kao is named as Director on the Form D that Delfi Diagnostics, Inc. filed with the SEC on 18 December 2025, one of 11 people that filing names.
Jacob Van Naarden is named as Director on the Form D that Delfi Diagnostics, Inc. filed with the SEC on 18 December 2025, one of 11 people that filing names.
11 people named on the filing — 4 holding an executive role and 7 as directors only.
Named as of the 2025-12-18 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about Delfi Diagnostics, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Delfi Diagnostics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Delfi Diagnostics, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Delfi Diagnostics, Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind Delfi Diagnostics, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for Delfi Diagnostics, Inc.. With no account yet, you sign up free and land on the result.
On these lists: Biotech raises in San Francisco Bay Area
https://mentionfox.com/funding/delfi-diagnostics-inc-form-d-25000001